Related by context. All words. (Click for frequent words.) 69 registrational 68 otelixizumab 68 investigational therapies 68 omacetaxine mepesuccinate 68 BLA filing 68 obatoclax 68 Restanza 68 RIGScan CR 68 IMA# 67 Q#IR 67 ponatinib 67 #D#C# 67 deforolimus 67 personalized immunotherapy 67 Ceflatonin 67 MAA submission 67 alvespimycin 66 Panzem R NCD 66 epigenetic therapies 66 ganetespib 66 vemurafenib 66 enzastaurin 66 Phase Ib study 66 HuMax CD4 66 forodesine 66 Troxatyl 66 Firazyr 66 vosaroxin 65 CR# vcMMAE 65 torezolid phosphate 65 Archexin 65 NP2 Enkephalin 65 Exelixis XL# 65 velafermin 65 AP# [003] 65 OncoVEX GM CSF 65 ruxolitinib 65 DXL# 65 anti angiogenic therapy 65 tanespimycin 65 Xanafide 65 romidepsin 65 L BLP# 65 Tyrima 65 registrational trial 65 YONDELIS 65 Alzhemed TM 65 Genz # 65 ofatumumab 65 receptor tyrosine kinase inhibitor 64 ARIKACE ™ 64 MEK inhibitors 64 vascular disrupting agent 64 talactoferrin 64 PXD# 64 investigational humanized monoclonal antibody 64 Icatibant 64 Fodosine 64 XmAb# 64 alvimopan 64 Quinamed 64 omacetaxine 64 brentuximab vedotin SGN 64 LibiGel ® 64 Aurexis 64 elotuzumab 64 sunitinib malate 64 Serdaxin 64 favorable pharmacokinetic profile 64 pomalidomide 64 sapacitabine 64 Benlysta belimumab 64 reslizumab 64 GAP #B# 64 SUTENT 64 phase IIb trial 64 IRX 2 64 BEXXAR 64 Linjeta TM 64 MoxDuo IR 64 PRT# 64 lorvotuzumab mertansine 64 HGS# 64 CCX# 64 oral prodrug 64 bosutinib 64 Carfilzomib 64 Onconase 64 HuMax EGFr 64 indolent NHL 64 axitinib 64 Civacir 64 ONCONASE 64 GLP toxicology studies 64 regorafenib 64 vidofludimus 64 TBC# 64 ZK EPO 64 Pixuvri 64 Panzem 63 XYOTAX TM 63 PDE4 inhibitor 63 Voraxaze 63 preclinically 63 pralatrexate 63 Cloretazine ® 63 Panzem R 63 lumiliximab 63 phase IIb clinical 63 Vilazodone 63 relapsed SCLC 63 Nuvion 63 tezampanel 63 cancer immunotherapies 63 Bezielle 63 Omapro 63 Plicera 63 OvaRex R 63 PANVAC VF 63 Amigal 63 Azedra 63 NDA resubmission 63 Phenoptin 63 SNT MC# 63 TORISEL 63 anticancer compound 63 VITAL Trial 63 KIACTA ™ 63 Lu AA# 63 Androxal ® 63 CA4P 63 acyclovir Lauriad R 63 Urocidin 63 refractory Hodgkin lymphoma 63 GALNS 63 GW# [003] 63 HCV protease inhibitors 63 EndoTAG TM -1 63 multiple myeloma MM 63 CCR5 antagonist 63 isoform selective 63 IMGN# 63 Allovectin 7 63 Telatinib 63 orBec 63 HuLuc# 63 TroVax ® 63 CBLC# 63 teriflunomide 63 tubulin inhibitor 63 CRMD# 63 Zybrestat 63 Shigamabs ® 63 Marqibo 63 AEG# 63 Tarceva TM 63 UPLYSO 63 EndoTAG TM 63 OHR/AVR# 63 Amrubicin 63 metastatic CRC 63 faropenem 63 pertuzumab 63 Proxinium TM 63 chronic myeloid leukemia CML 63 Aplidin 63 Virulizin ® 62 Surfaxin LS 62 atacicept 62 oral taxane 62 trastuzumab DM1 T DM1 62 INT# [002] 62 CINTREDEKIN BESUDOTOX 62 CAPHOSOL 62 ASONEP 62 tivozanib 62 phase IIa clinical 62 Allovectin 7 ® 62 PROSTVAC TM 62 Hsp# inhibition 62 oral ridaforolimus 62 Allovectin 7 R 62 Symadex 62 Linjeta ™ 62 GFT# 62 TPI ASM8 62 Phase IIb trials 62 lapatinib Tykerb 62 FOLOTYN ® 62 depsipeptide 62 Pimavanserin 62 AMPK activators 62 Abiraterone acetate 62 RezularTM 62 Bioral Amphotericin B 62 rilonacept 62 IND submission 62 Evoltra 62 Evoltra TM 62 Phase Ib II 62 eTag assays 62 ATL/TV# 62 OncoVEX 62 NEUMUNE 62 HGS ETR1 62 Orazol 62 Phase #b/#a 62 Augment Injectable 62 Triapine 62 OvaRex ® MAb 62 JAK inhibitor 62 Ceflatonin R 62 ALN TTR 62 ATL# [001] 62 Factor VIIa 62 Phase IIb clinical trials 62 Corlux 62 Phase #b/#a clinical 62 ELACYT 62 StemEx R 62 Cloretazine 62 LymphoStat B 62 zanolimumab 62 Phase #/#a 62 mapatumumab 62 eniluracil 62 MGCD# [001] 62 anticancer therapies 62 HQK 62 severe gastroparesis 62 refractory APL 62 Mipomersen 62 Multiferon ® 62 celgosivir 62 abiraterone acetate 62 Poly ICR 62 EOquin 62 Mepact 62 Fx #A 62 INCB# [001] 62 Chemophase 62 BrachySil TM 62 novel oral anticoagulant 62 predictive biomarkers 62 CoFactor 62 Menerba 62 ixabepilone 62 GED aPC 62 ADVEXIN 62 glufosfamide 62 PEG SN# 62 Orphan Drug designations 62 lomitapide 62 CINQUIL 62 nilotinib 62 BENLYSTA ® 62 Cimzia TM 62 MyVax R 62 Traficet EN 62 MEK inhibitor RDEA# 62 BRAF inhibitor 62 Anavex #-# 62 LEUKINE 62 Personalized Immunotherapy 62 Tasimelteon 62 neratinib 62 OMNARIS Nasal Spray 62 Phase 2a clinical trials 62 maribavir 62 Atiprimod 61 ACZ# 61 LHRH antagonists 61 elacytarabine 61 amrubicin 61 phase IIb study 61 SUCCEED trial 61 REG1 61 Diamyd ® 61 SAR# [004] 61 PEG PAL 61 HspE7 61 clinical pharmacology studies 61 biologic therapy 61 eprotirome 61 tamibarotene 61 immunosuppressant therapies 61 Elagolix 61 CYT# potent vascular disrupting 61 hematological cancers 61 rALLy trial 61 nosocomial pneumonia 61 Cethromycin 61 T#I mutation 61 thymalfasin 61 drug eluting stent DES 61 tocilizumab 61 Pazopanib 61 bardoxolone 61 cystinosis patients 61 PSN# [002] 61 Firazyr ® 61 MAXY G# 61 ProSavin 61 ALN PCS 61 Insegia 61 PREOS 61 dasatinib Sprycel 61 PROVENGE sipuleucel T 61 CIMZIA TM 61 crizotinib PF # 61 PEP# [003] 61 CIMZIA ™ 61 Revimmune 61 ThGRF 61 non metastatic osteosarcoma 61 RIGScan 61 PDX pralatrexate 61 Rezular 61 VitiGam 61 MabCampath 61 BRAF inhibitors 61 Toraymyxin TM 61 HCD# [002] 61 TOCOSOL Paclitaxel 61 BLA submission 61 Fibrillex TM 61 Phase 2a trial 61 BiovaxID TM 61 tafamidis 61 FOLOTYN 61 MyVax ® 61 SCH # 61 VitiGam TM 61 ProLindac 61 PREOS R 61 siRNA therapeutics 61 heterozygous FH 61 Omacetaxine 61 p# inhibitor 61 TriRima 61 Troxatyl TM 61 desvenlafaxine 61 metaglidasen 61 APPRAISE 61 Hedgehog inhibitor 61 Diamyd R 61 Hemopurifier ® 61 R#/MEM # 61 Octreotide 61 rALLy clinical trial 61 bevacizumab Avastin ® 61 Certican 61 plasma kallikrein inhibitor 61 Pirfenidone 61 amifampridine phosphate 61 Fibrillex 61 BZL# 61 PRTX 61 BCR ABL inhibitors 61 ZOLINZA 61 Provecta 61 Glybera R 61 liprotamase 61 PI3K inhibitors 61 iclaprim 61 lintuzumab 61 Stedivaze 61 Dacogen injection 61 Velcade bortezomib 61 ganaxolone 61 cMET 61 MyVax personalized immunotherapy 61 liposomal formulation 61 VEGF inhibitor 61 AZILECT ® 61 Aquinox 61 cabozantinib 61 HGS ETR2 61 Bronchitol 61 tolevamer 61 dasatinib 61 MGN# 61 Voraxaze ™ 61 tipranavir 61 OMNARIS HFA 61 CEQ# 61 Hedgehog antagonist 61 RhuDex ® 61 Perifosine 61 eliglustat tartrate 61 refractory CLL 61 SinuNase TM 61 Telaprevir 61 talabostat 61 Neuradiab 61 Octreolin 61 human microdosing 61 indibulin 61 RLY# 61 Reverset 61 QTinno TM 61 inhaled liposomal ciprofloxacin 61 MOZOBIL 61 Solorel TM 61 mRCC 61 Delcath PHP System 60 Genentech Roche 60 PCK# 60 Huntexil 60 AEGR 60 CytoFabTM 60 ONCONASE R 60 pexiganan 60 FACTIVE tablets 60 sNDA submission 60 huN# DM1 60 Orphan Designation 60 dirucotide 60 liposome formulations 60 BEMA TM Fentanyl 60 zalutumumab 60 ATryn ® 60 briakinumab 60 monoclonal antibody therapeutics 60 Eribulin 60 TREANDA 60 Viramidine 60 Veronate 60 Vandetanib 60 TG# [003] 60 JAK2 inhibitor 60 rALLy 60 tesmilifene 60 Zemplar Capsules 60 Nexavar sorafenib 60 lupus nephritis 60 canakinumab 60 relapsed MCL 60 Gleevec resistant 60 Zenvia ™ 60 riociguat 60 TACI Ig 60 triphendiol 60 PROCHYMAL 60 Ambrisentan 60 figitumumab 60 Viprinex 60 pradefovir 60 BAL# [002] 60 AZILECT R 60 Zingo TM 60 RGB # 60 blinatumomab 60 alogliptin 60 ISTODAX 60 glucokinase activator 60 Ereska 60 SUTENT ® 60 BioMarck 60 samalizumab 60 VAPRISOL 60 mifamurtide 60 PROSTVAC ® 60 Japanese Encephalitis vaccine 60 cangrelor 60 Zevalin consolidation 60 SinuNase 60 Pafuramidine 60 maximally tolerated dose 60 Dyloject TM 60 velaglucerase alfa 60 lucinactant 60 QNEXA 60 bicifadine 60 IMC A# 60 Rhucin R 60 ezogabine 60 gastrointestinal stromal tumors GIST 60 haematological cancers 60 drug ISA# 60 ILUVIEN ® 60 CCR9 antagonist 60 opioid bowel dysfunction 60 MAXY alpha 60 URG# 60 antibody MAb 60 Ophena 60 Trofex 60 Catena ® 60 MAGE A3 ASCI 60 eltrombopag 60 tramiprosate 60 generation purine nucleoside 60 Phase #/#a trial 60 PS# [001] 60 AMN# [001] 60 incyclinide 60 oral FTY# 60 IIa trial 60 L MTP PE 60 delafloxacin 60 CCR5 inhibitor 60 Vascular Wrap TM 60 NeuVax 60 nonclinical studies 60 heavily pretreated 60 Evoltra ® 60 PI3K/Akt pathway inhibitor 60 IL# PE#QQR 60 tecarfarin 60 mTOR kinase 60 Golimumab 60 superficial bladder cancer 60 ENMD # 60 Exherin TM 60 PIX# [002] 60 Campath alemtuzumab 60 biodefense countermeasure 60 CTAP# Capsules 60 IPLEX 60 ELND# 60 denufosol 60 Phase 2b study 60 Hedgehog Pathway Inhibitor 60 Junovan 60 sunitinib 60 DAVANAT R 60 Phase 1b trial 60 CCR5 inhibitors 60 NV1FGF 60 Pralatrexate 60 TNF alpha inhibitor 60 mertansine 60 CAMPATH 60 Gleevec Glivec 60 clofarabine 60 investigational compound 60 GRN# 60 DCCR 60 ALN TTR# 60 AAG geldanamycin analog 60 lymphoid malignancies 60 Zelrix 60 CYT# 60 radiation sensitizer 60 MET inhibitor 60 Nanobody 60 Multiferon R 60 CRD5 60 Diabetic Macular Edema 60 castrate resistant prostate cancer 60 Hepatocellular Carcinoma HCC 60 JNJ Q2 60 Orphan Drug status 60 confirmatory Phase III 60 MAXY VII 60 Vertex telaprevir 60 NEUGENE 60 rindopepimut 60 BLP# Liposome Vaccine 60 M Enoxaparin 60 ularitide 60 Dasatinib 60 abiraterone 60 Bafetinib 60 clevidipine 60 NVA# 60 BEMA Granisetron 60 invasive candidiasis 60 therapeutic monoclonal antibody 60 HCV infection 60 EndoTAGTM 1 60 trastuzumab DM1 59 teduglutide 59 gefitinib Iressa 59 Zoraxel 59 HERmark 59 phase Ib 59 Cinryze ™ 59 ATryn R 59 A3 adenosine receptor 59 ALN VSP 59 refractory PTCL 59 metastatic RCC 59 bendamustine 59 Phase Ib 59 ALK inhibitors 59 HER2 positive metastatic breast 59 Telavancin 59 Dalbavancin 59 Elocalcitol 59 myelofibrosis 59 Myocet 59 T#I [002] 59 Loramyc R 59 AeroLEF TM 59 myeloproliferative disorders 59 TEMODAL 59 HRPC 59 masitinib 59 Cladribine Tablets 59 Targretin 59 Atu# 59 recombinant biopharmaceutical 59 olaparib 59 DPX Survivac 59 Asentar 59 AGHD 59 Angiocept 59 BCG refractory 59 RSR# 59 ZACTIMA 59 INC# 59 vaginal lidocaine 59 USL# 59 RH1 59 favorable tolerability 59 KRN# 59 PSN# [001] 59 Raptiva ® 59 relapsed refractory multiple myeloma 59 PNP inhibitor 59 CDP# 59 Davanat 59 TRV# [001] 59 Ceplene TM 59 biologic therapies 59 dalbavancin 59 vascular disrupting agents 59 JAK inhibitors 59 antithrombotics 59 Bendavia 59 Cardio Vascu Grow 59 cediranib 59 neoadjuvant treatment 59 Tamibarotene 59 picoplatin 59 inhaled AAT 59 registrational trials 59 Tracleer r 59 EOquin TM 59 pharmacokinetic PK study 59 Pertuzumab 59 TLR antagonists 59 TRO# 59 LE DT 59 ATL# [002] 59 Talabostat 59 elvucitabine 59 dose escalation Phase 59 rxRNA 59 DermaVir Patch 59 WILEX 59 pharmacokinetic PK 59 Renal Cell Carcinoma RCC 59 tezampanel NGX# 59 Campath ® 59 genomic biomarker 59 histone deacetylase HDAC inhibitor 59 immunotherapeutic vaccine 59 trabectedin 59 optimal dosing 59 CA9 SCAN 59 ozarelix 59 dose cohort 59 PLK1 SNALP 59 Daniel Junius 59 oritavancin 59 preclinical efficacy 59 MDS AML 59 Zemiva TM 59 Dr. McHutchison 59 STRIDE PD 59 Rhucin 59 CRLX# 59 Torisel 59 Afatinib 59 casopitant 59 midstage studies 59 Intravenous CP 59 Treanda 59 NADiA ProsVue 59 tiapamil 59 ADAGIO study 59 tipifarnib 59 miconazole Lauriad ® 59 Plenaxis TM 59 vilazodone 59 Zerenex 59 viral kinetics 59 carfilzomib 59 Kamada AAT 59 Clolar 59 LymphoStat B belimumab 59 Nabi HB Intravenous 59 SPARLON 59 efficacy endpoint 59 antithrombotic 59 prospectively defined 59 orphan designation 59 efficacy tolerability 59 Alferon N 59 brivaracetam 59 antiviral therapy 59 SYMMETRY trial 59 predictive biomarker 59 Orphan Status 59 T DM1 59 Reolysin 59 BCR ABL inhibitor 59 ticagrelor Brilinta 59 NNR Therapeutics 59 eribulin mesylate 59 Arzerra ofatumumab 59 sJIA 59 DOS# 59 Anthim 59 ritonavir boosted danoprevir 59 MyVax 59 Ceflatonin ® 59 DPP4 inhibitor 59 HCV protease 59 Tracleer R 59 apricitabine 59 Silodosin 59 Harry Palmin President 59 herpetic keratitis 59 ulimorelin 59 Folotyn 59 dosing cohort 59 PROVENGE ® 59 anidulafungin 59 Altastaph 59 Arcalyst 59 Anticalin R 59 IGF 1R inhibitor 59 refractory chronic lymphocytic 59 ATIR 59 fosbretabulin 59 TOLAMBA 59 APF# 59 Onalta ™ 59 Spiegelmer ® 59 HSP# inhibitor 59 Prodarsan ® 59 acetonide FA 59 assessing T DM1 59 Pemetrexed 59 TELCYTA 59 EGS# 59 Glufosfamide 59 DACH platinum 59 BENLYSTA 59 PSMA ADC 59 pain palliation 59 refractory AML 59 BCX# 59 systemic fungal infections 59 Annamycin 59 Glybera 59 Zensana TM 59 Ketotransdel 59 AVP #D# 59 galiximab 59 SILENOR 59 bardoxolone methyl 59 pazopanib 59 refractory gout 59 ON #.Na 59 Panzem NCD 59 Endeavor DES 59 non nucleoside HCV 59 histamine dihydrochloride 59 vandetanib 59 GVAX 59 BAY #-# 59 palifosfamide 59 Phase Ib clinical 59 beta 1a 59 adipiplon 59 Nasulin 59 refractory metastatic 59 motesanib 59 IMC #B 59 mitogen activated ERK kinase 59 iniparib 59 ENRICH trial 59 Nanobody ® 59 Biologic License Application BLA 59 Avastin bevacizumab 59 pulmonary arterial hypertension PAH 59 imatinib resistance 59 baminercept 59 cilengitide 59 Bicifadine 59 SinuNase ™ 59 StaphVAX 59 ZYBRESTAT 59 FIRMAGON R 59 docetaxel Taxotere R 59 PROMACTA 59 Phase #b/#a trial 59 Actimmune ® 59 OPAXIO 59 Excellagen 59 BRIM2 59 rhThrombin 59 PHX# 59 ZYBRESTAT fosbretabulin 59 Northera 59 Poly ICLC 59 therapeutic regimens 59 Guanilib 59 zileuton IV 59 BIM #A# 59 volociximab 59 metastatic sarcomas 59 nalbuphine ER 59 Oglemilast 59 ospemifene 59 Revlimid lenalidomide 58 Glypromate 58 radezolid 58 decitabine 58 Chimigen TM 58 AQ4N 58 Marketing Authorisation Application 58 MEND CABG II 58 Ophena TM 58 Junovan TM 58 Azedra TM 58 relapsed multiple myeloma 58 metastatic renal cell 58 biliary tract cancer 58 perifosine 58 seliciclib CYC# 58 Aflibercept 58 relapsed ovarian cancer 58 rNAPc2 58 Solorel 58 daclizumab 58 IRESSA 58 angiogenesis inhibitor 58 Phase III TRIST 58 Entereg R 58 Bayer Onyx 58 lintuzumab SGN 58 Genasense ® 58 CD# antibody [001] 58 Zalbin 58 TRISENOX 58 antithrombotic therapy 58 daptomycin 58 zileuton 58 OXi# 58 terlipressin 58 telaprevir VX 58 synthetic retinoid 58 INCB# [002] 58 chemotherapeutic regimen 58 apricitabine ATC 58 ZEVALIN ® 58 REMINYL ® 58 alagebrium 58 Virulizin R 58 oral PTH 58 AzaSite Plus 58 Telintra 58 Evoltra R 58 Leukine 58 Zavesca ® 58 targeted radiotherapeutic 58 recombinant factor VIIa 58 epratuzumab 58 Squalamine 58 molecularly targeted 58 TroVax 58 Technosphere Insulin 58 Arranon 58 XmAb 58 HuMax CD# 58 orally bioavailable 58 Cloretazine R 58 apremilast 58 HoFH 58 afatinib 58 brentuximab vedotin 58 Mpex 58 Hsp# inhibitor tanespimycin 58 Sym# 58 oral salmon calcitonin 58 atrasentan 58 tyrosine kinase inhibitors 58 Onco TCS 58 RenalGuard TM 58 NUVIGIL 58 secondary efficacy endpoints 58 anti angiogenic agents 58 brostallicin 58 R roscovitine 58 ADVEXIN therapy 58 THALOMID 58 Advexin 58 MBP# [001] 58 Tarceva erlotinib 58 forodesine hydrochloride 58 Triapine R 58 NPSP# 58 BrachySil 58 Aryplase 58 XP #L 58 AERx iDMS 58 mTOR inhibitor 58 SPRYCEL ® 58 AVN# [001] 58 JAK1 58 DAVANAT 58 Removab 58 NEBIDO 58 BNC# 58 LibiGel ® testosterone gel 58 ZEVALIN 58 fluoropyrimidine 58 HCV antiviral 58 fidaxomicin 58 proteasome inhibitor 58 epothilone 58 Theratope 58 TAFA# 58 DCVax R 58 thalidomide Thalomid 58 Neo Kidney Augment ™ 58 trastuzumab emtansine T DM1 58 Apaziquone 58 midstage trials 58 THR beta agonist 58 monoclonal antibody therapies 58 Activity Assay 58 recurrent GBM 58 Phase IIB 58 Ozarelix 58 LEVADEX ™ 58 Vernakalant 58 cytotoxics 58 adecatumumab 58 Xinlay 58 Degarelix 58 Prestara 58 SERMs 58 CD# monoclonal antibody 58 oral rivaroxaban 58 Zenvia Phase III 58 PIX# trial 58 phase IIb 58 Emezine 58 Omigard 58 YONDELIS R 58 Ocrelizumab 58 Phase IIa trial 58 multi kinase inhibitor 58 cardio renal 58 BRIM3 58 anti leukemic 58 Locteron ® 58 acute GvHD 58 AQUAVAN R 58 recurrent glioblastoma 58 Manja Bouman CEO 58 systemic immunosuppressive drugs 58 molecular entities NMEs 58 MAbs 58 APTIMA HPV assay 58 HZT 58 GSK# [002] 58 oral methylnaltrexone 58 GEM OS2 58 TELINTRA 58 delta isoform 58 Nebido 58 Iluvien ® 58 MabThera rituximab 58 Ramoplanin 58 RNAi therapeutic targeting 58 HDACi 58 successfully commercialize Iluvien 58 MDV# 58 etravirine 58 Phase III trials 58 SURFAXIN 58 Microplasmin 58 TKM ApoB 58 gepirone ER 58 candidate TNFerade biologic 58 Behcet uveitis 58 Pegloticase 58 Prostate AdenoCarcinoma Treatment 58 renin inhibition 58 Pyridorin 58 Muraglitazar